CARM Stock Forecast 2025-2026
Distance to CARM Price Targets
CARM Price Momentum
10 Quality Stocks Worth Considering Now
Researching Carisma (CARM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CARM and similar high-potential opportunities.
Latest CARM Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, CARM has a neutral consensus with a median price target of $1.00 (ranging from $1.00 to $1.00). Currently trading at $0.19, the median forecast implies a 420.8% upside. This outlook is supported by 1 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 420.8% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 420.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CARM Analyst Ratings
CARM Price Target Range
Latest CARM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CARM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $1.00 |
| Jan 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Jan 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| Dec 12, 2024 | Baird | Neutral | Downgrade | $0.00 | |
| Dec 12, 2024 | D. Boral Capital | Buy | Maintains | $0.00 | |
| Dec 11, 2024 | Evercore ISI Group | Liisa Bayko | In-Line | Downgrade | $0.70 |
| Dec 10, 2024 | BTIG | Justin Zelin | Neutral | Downgrade | $0.00 |
| Dec 9, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $12.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $5.00 |
| Nov 18, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $24.00 |
| Nov 11, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $24.00 |
| Nov 7, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $24.00 |
| Oct 30, 2024 | EF Hutton | Jason Kolbert | Buy | Initiates | $24.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $8.00 |
| Jun 26, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $8.00 |
| May 17, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $8.00 |
| May 10, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $8.00 |
| Apr 11, 2024 | BTIG | Justin Zelin | Buy | Initiates | $6.00 |
| Apr 2, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $9.00 |
Carisma Therapeutics Inc. (CARM) Competitors
The following stocks are similar to Carisma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Carisma Therapeutics Inc. (CARM) Financial Data
Carisma Therapeutics Inc. has a market capitalization of $8.02M with a P/E ratio of -0.1x. The company generates $19.63M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -14.8% quarter-over-quarter, while maintaining an operating margin of -434.0% and return on equity of +216.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Carisma Therapeutics Inc. (CARM) Business Model
About Carisma Therapeutics Inc.
Develops innovative cellular therapies for cancer.
Carisma Therapeutics Inc. focuses on creating advanced immunotherapies that utilize chimeric antigen receptor macrophages (CAR-M) to target and eliminate cancer cells. The company generates revenue through partnerships, collaborations, and potentially through the commercialization of its therapies as they progress through clinical trials and regulatory approvals.
Headquartered in Philadelphia, Carisma is positioned in a key healthcare research hub, enhancing its access to resources and expertise. The company is at the forefront of oncology therapeutics, making significant contributions to the biotechnology and healthcare sectors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
46
CEO
Mr. Steven Kelly
Country
United States
IPO Year
2014
Website
www.carismatx.comCarisma Therapeutics Inc. (CARM) Latest News & Analysis
Carisma Therapeutics Provides Corporate Updates
19 days agoCarisma Therapeutics (Nasdaq: CARM) is exploring strategic alternatives to enhance its liver fibrosis and oncology assets while reducing cash burn, aiming to maximize value from its platforms and agreements.
Carisma Therapeutics is restructuring to cut costs and enhance asset value, which could impact its stock performance and future funding, influencing investor sentiment and market positioning.
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
2 months agoCarisma Therapeutics Inc. (Nasdaq: CARM) announced that Co-founder and Chief Scientific Officer Michael Klichinsky will speak at the H.C. Wainwright Cell Therapy Virtual Conference on February 25.
Michael Klichinsky's participation in a prominent conference highlights Carisma's leadership in cell therapy, potentially boosting investor confidence and interest in the company's growth prospects.
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
2 months agoCarisma Therapeutics Inc. (Nasdaq: CARM) CEO Steven Kelly will speak at the Oppenheimer Healthcare Life Sciences Conference on February 11 at 4:40 pm ET. An audio webcast will be available post-event.
Carisma Therapeutics' CEO's participation in a major healthcare conference highlights its visibility and potential for investor interest, signaling developments in its therapeutic innovations.
Carisma Therapeutics (Nasdaq: CARM) will discontinue CT-0525 development and cut its workforce by 34% to focus on in vivo macrophage engineering for fibrosis, oncology, and autoimmune therapies.
Carisma Therapeutics is shifting focus to its macrophage engineering platform while discontinuing CT-0525 and cutting jobs, signaling a strategic pivot that could impact future growth and investor confidence.
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
4 months agoCarisma Therapeutics (Nasdaq: CARM) CEO Steven Kelly will speak at the Evercore ISI HealthCONx Conference on December 5 at 9:35 am ET. An audio webcast will be available on their Investor Relations page.
Carisma Therapeutics' CEO participation in a prominent conference highlights the company's visibility and potential, potentially influencing investor sentiment and stock performance.
Carisma Therapeutics presented preclinical data showing engineered macrophages effectively treat liver fibrosis, highlighting their potential as a novel therapy for fibrotic liver diseases.
Promising preclinical data on Carisma's engineered macrophages could enhance its market position, attract investment, and potentially lead to significant revenue from treating liver fibrosis.
Frequently Asked Questions About CARM Stock
What is Carisma Therapeutics Inc.'s (CARM) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Carisma Therapeutics Inc. (CARM) has a median price target of $1.00. The highest price target is $1.00 and the lowest is $1.00.
Is CARM stock a good investment in 2025?
According to current analyst ratings, CARM has 1 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CARM stock?
Wall Street analysts predict CARM stock could reach $1.00 in the next 12 months. This represents a 420.8% increase from the current price of $0.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Carisma Therapeutics Inc.'s business model?
Carisma Therapeutics Inc. focuses on creating advanced immunotherapies that utilize chimeric antigen receptor macrophages (CAR-M) to target and eliminate cancer cells. The company generates revenue through partnerships, collaborations, and potentially through the commercialization of its therapies as they progress through clinical trials and regulatory approvals.
What is the highest forecasted price for CARM Carisma Therapeutics Inc.?
The highest price target for CARM is $1.00 from Jason Kolbert at D. Boral Capital, which represents a 420.8% increase from the current price of $0.19.
What is the lowest forecasted price for CARM Carisma Therapeutics Inc.?
The lowest price target for CARM is $1.00 from Jason Kolbert at D. Boral Capital, which represents a 420.8% increase from the current price of $0.19.
What is the overall CARM consensus from analysts for Carisma Therapeutics Inc.?
The overall analyst consensus for CARM is neutral. Out of 7 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are CARM stock price projections?
Stock price projections, including those for Carisma Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.